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Introduction: More effective regimens are urgently needed for
squamous cell carcinoma of esophagus (SCCE), therefore, we con-
ducted a phase I/II trial of a combination of docetaxel, platinum, and
fluorouracil (TPF) for treating metastatic SCCE.
Methods: This phase I/II trial (n  12/39) was conducted in our
institute from April 2005 to June 2008. Progression-free survival
(PFS) and overall survival were analyzed by the Kaplan-Meier
method.
Results: The recommended dose of docetaxel was determined to be
50 mg/m2 in phase I. In phase II with a mean follow-up period of
13.3 months, the objective response rate was 66.6%, a median
survival period of 13 months and PFS of 7 months was achieved,
and the 1-year survival and PFS rates were 52.9% and 19.6%,
respectively. Grade 3/4 toxicities of leukopenia, neutropenia, and
anorexia were observed in 53.8%, 43.6%, and 25.6%, respectively.
Conclusions: A TPF regimen against metastatic SCCE was well
tolerated and achieved a favorable objective response rate and
survival benefit compared with other recently reported regimens.
Randomized phase III trials of the TPF regimen are warranted and
urgently required.
Key Words: Chemotherapy, Docetaxel (TXT), Squamous cell car-
cinoma, Esophagus.
(J Thorac Oncol. 2010;5: 122–128)
The most effective chemotherapeutic regimens againstadvanced esophageal carcinoma remain to be estab-
lished. Squamous cell carcinoma of the esophagus (SCCE)
has the poorest prognosis among the gastrointestinal
cancers and is often discovered in its late stages with
metastatic spread; consequently, 5-year survival remains
around 10%.1 Both in Japan and in Europe and America,21
fluorouracil (FU) and platinum combination treatment (FP)
is regarded as the standard palliative chemotherapy for
advanced esophageal cancer. In Japan, the objective re-
sponse rate (ORR) is modest at 35.9%, and median sur-
vival time (MST) is reported to be 9.2 months for respond-
ers and 5.3 months for nonresponders.3 In Europe and
America, ORR is reported to be 34 to 48.6%, MST 6.4 to
13 months, and 1-year survival rate 31 to 39%.4–6 Collec-
tively, the survival benefit of the FP regimen compared
with best supportive care has not yet been established.
In contrast, for advanced head and neck cancer or
gastric cancer, success has recently been reported7–9 using
FP combined with docetaxel (TXT; Taxotere, Sanofi-
Aventis, Paris, France), which enhances microtubule as-
sembly and inhibits tubulin depolymerization, thereby pre-
venting cell division.10,11 A Japanese phase II study of
TXT in metastatic esophageal cancer12 produced an overall
ORR of 20.4%, with major toxicities (grade 3/4) being
neutropenia (87.8%) and leukopenia (73.5%). Recent trials
include TXT added to FP treatment with concurrent radio-
therapy for advanced esophageal cancer,13 a TPF regimen as
second-line therapy for metastatic disease,14,15 and TPF in a
neoadjuvant setting.16 Recently, various new combinations, but
not FP that incorporated TXT, for esophageal cancer have been
tested, in which ORR was reported to be 24 to 48% and MST 8
to 11 months.17,18
To date, there have been few reports of TPF treatment
specifically confined to SCCE. In Japan, squamous cell can-
cer (SCC) predominates, accounting for approximately 92%
of cases of esophageal cancer;19 in contrast, adenocarcinoma
has been increasing rapidly in Europe and America.20 Com-
pared with adenocarcinoma, SCC seems to be more sensitive
to chemotherapy, chemoradiation, and radiation therapy even
if the long-term outcomes are inconsistent,21 but these differ-
ences highlight the need for separate studies of each histo-
logic type.4,6,18,22,23 Therefore, we conducted a phase I/II trial
to determine the antitumor effect and safety of TPF for
Japanese SCCE.
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PATIENTS AND METHODS
Inclusion and Exclusion Criteria
All the 46 participants were histopathologically con-
firmed to have SCCE. Criteria for inclusion were age 20 to 80
years, Eastern Cooperative Oncology Group performance
status within 0 to 2, measurable target lesions, stage IV or
recurrent disease, main organ functions retained, and 2
months or more of life expectancy. Exclusion criteria in-
cluded overt infection (more than 38°C or C-reactive protein
7.5 mg/dl); presence of serious complications (heart dis-
ease, pulmonary fibrosis, interstitial pneumonia, bleeding
tendency, etc.); peripheral nerve symptoms except for those
caused by the primary disease; active double primary cancers;
present or previous brain metastases, pleural effusion, ascites,
pericardial effusion, and edema needing treatment; history of
drug hypersensitivity; pregnancy; or breast feeding. Finally,
we also excluded women considering pregnancy and patients
receiving long-term steroids. All the participants gave fully
informed written consent based on the Helsinki Declaration.
The institutional review board of the Keiyukai Sapporo Hos-
pital approved the study protocol.
Treatment Plan
We adopted a two-stage design; the first stage to de-
termine the optimal safe dosages for TPF treatment (phase I,
n  12), and the second to assess the precise antitumor
activity and safety of the TPF combination using the dosages
determined in the first stage (phase II, n  39). We judged
antitumor effect in accordance with “Guidelines for Clinical
and Pathologic Studies on Carcinoma of the Esophagus”
established by the Japanese society of esophagus,24 whereas
for safety assessment, we followed the “Common Terminol-
ogy Criteria for Adverse Events v3.0.” The treatment was
continued until patients met one of the following discontin-
uation criteria: development of serious side effects, clear
evidence of progressive disease (PD), treatment continuation
deemed difficult by virtue of new diseases, exacerbation of
complications, or for any reasons judged by the attending
doctors. Treatment was also discontinued when exclusion
criteria became evident after initiating the treatment, when-
ever recovery from adverse events did not meet the restart
criteria even if it was more than 6 weeks from the last
administration, and whenever nervous system disorder
judged as grade 3 or more developed.
The dosage of docetaxel was increased according to the
following scale: 40 mg/m2 as level 1, 50 mg/m2 as level 2,
and 60 mg/m2 as level 3, whereas the dosage of cisplatin
(CDDP) and FU was fixed at 70 mg/m2 and 700 mg/m2,
respectively. The administration schedule began with do-
cetaxel dissolved in 250 to 500 ml and intravenously infused
for 60 to 120 minutes on day 1, and a maintenance infusion
given for the next 3 hours. CDDP was then infused for 120
minutes. FU was continuously infused from day 1 to day 5.
This regimen comprised one course and was repeated every 3
weeks. Dose-limiting toxicity (DLT) was defined as follows:
either grade 4 leukopenia or neutropenia continuing for more
than 5 days; grade 3 or greater neutropenia with pyrexia of
38°C; grade 4 thrombocytopenia; nonblood toxicity of grade
3 except for anorexia, nausea, vomiting, and hair loss. TPF
was scheduled to be administered to three patients for each of
the three levels, and if DLT did not develop in any of the
three patients, the dose was increased to the next level.
However, if DLT developed in all three patients, that dosage
was defined as the maximum tolerance dose (MTD). When
DLT developed in one or two patients of the three, another
three patients were added at the same level. If two or fewer
patients of the six showed DLT, the dose was increased to the
next level, but if three patients or more showed DLT, that
dosage was determined to be the MTD. In the second stage,
more than two courses of chemotherapy were integral to this
study.
Statistical Analysis
The primary end points of this phase I/II study were to
report ORR and descriptive summaries of adverse events and
secondary end points including progression-free survival
(PFS) and overall survival (OS). A confidence interval for the
percentage of patients with a tumor response was calculated
by the method of Duffy and Santner.25 The number of
patients to be enrolled was determined using a modified
multistage Fleming design26 based on an expected TPF re-
sponse rate of 65% and a nonresponse rate of 30%, with 
error of 0.05 (two-tailed) and  error of 0.2. The required
number of patients was calculated as 31. An interim analysis
was planned after the first nine patients were enrolled. If none
of the nine patients had a partial or complete response, the
trial was to be stopped. If a major objective response was
confirmed in any of the first 9 patients studied, accrual was to
be continued to a total of more than 31 patients. OS was
measured from the start. Statistical analysis was conducted
using the SPSS version 11.5.1J (SPSS Japan Inc., Tokyo,
Japan). A difference was considered significant when P
0.05 in all two-tailed tests. The Kaplan-Meier method with
the log-rank test was used for survival analysis. OS and PFS
TABLE 1. Clinicopathologic Features in Phase I Patients
Age
Mean (yr) 63.9
Range (yr) 53–74
Gender
Male/female 10/2
ECOG PS
0/1 10/2
Disease status
Metastatic/recurrent 9/3
Location of tumor
Cervical 0
Thoracic 10
Abdominal 2
Metastatic organ
M1 lymph node 4
Liver 5
Lung 3
ECOG, Eastern Cooperative Oncology Group; PS, performance status.
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were measured from the date of initiating chemotherapy to
death from any cause and PD, respectively.
RESULTS
Phase I
Twelve patients were consecutively enrolled from April
2005 to February 2006. Demographic features of the study
population are shown in Table 1. Twenty-five percent (3 of
12) of the patients had previously received chemoradiother-
apy. Blood and nonblood toxicities in this phase are summa-
rized in Table 2. At level 1, two patients had grade 3
neutropenia (66.6%) and one patient had grade 3 leukopenia
(33.3%), and two patients developed grade 3 nausea as a
nonblood toxicity, which did not meet the criteria of DLT. At
level 2, one patient among the first three patients developed
febrile neutropenia, leukopenia, and thrombocytopenia, all of
which were compatible with grade 4, and this patient unfor-
tunately died of septic shock on the 24th day. Because the
remaining two patients did not develop any DLT, an addi-
tional three patients were enrolled at the same level 2.
Thrombocytopenia of grade 3, leukopenia, neutropenia, and
stomatitis developed in one of the three patients, but did not
meet the criteria for DLT, and the dose was increased to the
next level because only two of the six patients met the criteria
for DLT at level 2. At level 3, two patients developed febrile
neutropenia of grade 3 or more, and grade 4 neutropenia
persisted for more than 5 days. Grade 3 stomatitis developed
in the remaining patients and, consequently, all the patients
met the criteria for DLT. The level 3 dosage was defined as
the MTD and the level 2 dose was adopted as the recom-
mended dosage.
TABLE 2. Hematological and Nonhematological Toxicity
in Phase I
NCI-CTC Grade
Grades 3
and 4 (%)1 2 3 4
Hematological
Level 1 (n  3)
Leukopenia 1 1 1 0 1 (33.3)
Neutropenia 1 0 2 0 2 (66.6)
Anemia 1 2 0 0 0
Thrombocytopenia 1 0 0 0 0
Level 2 (n  6)
Leukopenia 2 2 1 1 2 (33.3)
Neutropenia 2 1 1 1 2 (33.3)
Anemia 2 2 1 0 1 (16.7)
Thrombocytopenia 0 1 1 1 2 (33.3)
Level 3 (n  3)
Leukopenia 0 0 3 0 3 (100)
Neutropenia 0 0 2 1 3 (100)
Anemia 3 0 0 0 0
Thrombocytopenia 0 0 0 0 0
Nonhematological
Level 1 (n  3)
Anorexia 1 1 1 0 1 (33.3)
Nausea 1 0 2 0 2 (66.6)
Vomiting 0 1 0 0 0
Diarrhea 1 1 0 0 0
Stomatitis 1 0 0 0 0
Alopecia 3 0 — — 0
Febrile neutropenia 0 0 0 0 0
Level 2 (n  6)
Anorexia 0 3 2 0 2 (33.3)
Nausea 0 2 3 0 3 (50.0)
Vomiting 0 0 1 0 1 (16.7)
Diarrhea 2 0 0 0 0
Stomatitis 1 1 1 0 1 (16.7)
Alopecia 2 0 — — 0
Febrile neutropenia 0 0 1 1 2 (33.3)
Level 3 (n  3)
Anorexia 0 0 3 0 3 (100)
Nausea 0 0 3 0 3 (100)
Vomiting 0 0 0 0 0
Diarrhea 0 1 0 0 0
Stomatitis 0 0 1 0 1 (33.3)
Alopecia 3 0 — — 0
Febrile neutropenia 0 0 2 0 2 (66.6)
NCI-CTC, National Cancer Institute Common Toxicity Criteria.
TABLE 3. Clinicopathologic Features in Phase II Patients
Age
Mean (yr) 65.2
Range (yr) 44–79
Gender
Male/female 34/5
ECOG PS
0/1 29/10
Disease status
Metastatic/recurrent 16/23
Location of tumor
Cervical 2
Thoracic 35
Abdominal 2
Metastatic organ
M1 lymph node 13
Liver 14
Lung 11
Bone 1
Stage
III 5
IV 34
Treatment cycle
Median 3.5
Range 2–12
Response rate (%)
CR 2 (5.1)
PR 24 (61.5)
ORR (66.6) 95% CI (49.8–80.9)
SD 12 (30.8)
PD 1 (2.6)
ECOG, Eastern Cooperative Oncology Group; PS, performance status; CR, com-
plete response; PR, partial response; ORR, objective response rate; SD, stable disease;
PD, progressive disease.
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Phase II
Including 5 of the 6 patients who received 50 mg/m2 of
TXT as level 2 in the phase I study (there was one therapy-
related death [TRD] in the phase I study as mentioned
earlier), a total of 39 patients were consecutively enrolled
from February 2006 to June 2008 and evaluated in phase II.
Clinicopathologic features of the participants are shown in
Table 3. There are 2 complete responses (5.1%), 24 partial
responses (61.5%), 12 stable diseases (30.8%), and 1 PD
(2.6%) in the therapeutic evaluation. Nine patients were alive
for the mean observation period of 13.3 months, of whom two
patients achieved PFS. The median survival period achieved
was 13 months; the 1-year and 2-year survival rates were
52.9% and 19.5%, respectively, as depicted in Figure 1A. The
median of PFS was 7 months; the 6-month and 1-year PFS
rates were 53.8% and 19.6%, respectively, as depicted in
Figure 1B. MST was better in the responder (15.6 months)
than in the nonresponder (9.7 months), which was marginally
significant (P  0.057, data not shown). The toxicity ob-
served in the phase II study is shown in Table 4. Leukopenia,
neutropenia, and anorexia were frequent. Grade 3/4 leukope-
nia and neutropenia were observed in 53.8% and 43.6%,
respectively. Febrile neutropenia and stomatitis of grade 3 as
representative nonblood toxicities were detected in 12.8% of
patients.
Twenty-seven patients (71.1%) received one or more of
the following coincidental treatments: surgical excision in 3
patients, chemoradiotherapy in 7, radiation alone in 4, and
second-line chemotherapies in 22. Second-line chemothera-
peutic regimens consisted of combined docetaxel plus
nedaplatin given in 11 patients, combined docetaxel plus FU
in 7 patients, nedaplatin monotherapy in 3 patients, and FP
therapy in 1 patient.
DISCUSSION
Advanced esophageal cancer carries a very poor prog-
nosis, with a MST of only 6 to 8 months with current
chemotherapies.27 A survival advantage for chemotherapy
over best supportive care alone in patients with metastatic
esophageal cancer has not been proven in randomized trials
nor has a standard and/or effective chemotherapeutic regimen
for first-line chemotherapy been clearly defined in this set-
ting. Even worse, most recent trials are nonrandomized,
small-scale phase II studies, which have included heteroge-
nous patient populations of both adenocarcinomas and SCC
as well as both locally advanced and metastatic disease of
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FIGURE 1. Overall survival (OS) and progression-free survival (PFS). A, OS by Kaplan-Meyer method. Median survival time
(MST) was 390 days (13 months), and 1-year survival rate was 52.9%. B, PFS was analyzed by Kaplan-Meyer method. MST
was 210 days (7 months), and 1-year survival rate was 19.6%.
TABLE 4. Hematological and Nonhematological Toxicity
in Phase II
NCI-CTC Grade
Grade 3
and 4 (%)1 2 3 4
Hematological
Leukopenia 6 11 18 3 21 (53.8)
Neutropenia 10 9 14 3 17 (43.6)
Anemia 14 18 2 0 2 (5.1)
Thrombocytopenia 3 4 4 0 4 (10.3)
Nonhematological
Anorexia 12 13 10 0 10 (25.6)
Nausea/vomiting 9 12 2 0 2 (5.1)
Diarrhea 10 9 3 0 3 (7.7)
Stomatitis 6 4 5 0 5 (12.8)
Alopecia 10 3 — — 0 (0)
Febrile neutropenia — — 5 0 5 (12.8)
NCI-CTC, National Cancer Institute Common Toxicity Criteria.
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gastric adenocarcinoma, esophageal adenocarcinoma, gastro-
esophageal junctional cancer, or SCCE, each of which should
require a different therapeutic approach.21 To date, clinical
studies of chemotherapy against unresectable SCCE have
failed to provide convincing evidence of efficacy. This is of
special concern in the homogenous Japanese population,
where SCCE is the most common (92%) form of esophageal
cancer. Although many high-quality studies have established
the efficacy of TPF treatment for head and neck and gastric
cancer, efficacy remains to be established for SCCE. We
believe that this is the first phase II study showing that TPF
could potentially be a first-line treatment for metastatic SCCE
(Table 5).
In this Japanese phase II evaluation of TPF, promising
results were obtained with an ORR of 66.6%, nearly double
than that of previous reports,4–6 and an MST of 13 months,
approximately 3 months longer than FP responders (9.2
months).3 Furthermore, MST in the responders to the FP
regimen was almost equivalent to MST for the nonresponders
to the TPF regimen. As shown in Table 5, previous studies on
two or more drug combinations of the three agents taxane,
CDDP, or FU were carefully selected on the basis of study
populations of both metastatic disease and predominant his-
tology of SCCE during the last decade. Surprisingly, there
were only five related studies from China, Japan, Italy, and
United States. Eliminating concurrent radiation and second-
line treatment from these studies, the results of the studies
reported by Zhang and Ilson were very similar; ORR, PFS,
and OS were 48.6%, 7 months, and 13 months in the first
study and 48%, 5.7 months, and 10.8 months in the second
study. Higuchi et al. in their phase I trial reported the
potential effectiveness of TPF and concurrent radiation ther-
apy, in which ORR accounted for 89.5% and OS reached up
to 20.0 months.13 Furthermore, in the last decade, several
attempts have been made to test new agents for SCCE,
especially cetuximab, taxanes, nedaplatin, irinotecan, vinorel-
bine, etc. (Table 6). The highest ORR (57.8%) with MST of
11.2 months was reported by Lee et al.33 The highest median
OS (11.6 months) with ORR of 50% was reported by Cho et
al.34 These findings suggest that the TPF regimen would be
superior to the FU regimen and comparable with other new
drug combination regimens and should be adopted as the
standard chemotherapy against advanced or metastatic SCCE.
Furthermore, TPF treatment should also be promising in the
concurrent radiation therapy13 and neoadjuvant setting.16
In comparison with 75 mg/m2 of TXT in TPF regimen
for advanced head and neck cancer7,8 and gastric cancer,9 or
60 mg/m2 in recent reports for SCCE,15,27 the recommended
dosage of TXT determined as 50 mg/m2 by the phase I seems
relatively small. Combined toxicity profile and scheduling
TABLE 5. Taxane/Cisplatin/Fluorouracil-Based Trials in Metastatic SCCE
Year Author No. of Patients Phase Regimen ORR PFS MST
2008 Zhang et al.4 39 PII PTX/CDDP 48.6 7.0 13.0
Higuchi et al.13 19 PI TPF/Rx (KDOG 0501) 89.5 10.6 20.0
2007 Tanaka et al.15 20 PII TPF (second line) 35.0 4.0 8.0
Chiarion-Sileni et al.27 37 PII TPF  CBDCA/Rx 49.0 9.8 10.8
1998 Ilson et al.28 61 (inclusion of 30 ADC) PII PTX/CDDP/FU 48.0 5.7 10.8
Table summarizes previously published comparative studies on two or more drug combination regimens from the three chemotherapeutic agents taxane,
cisplatin, or fluorouracil with or without radiation therapy. Studies restricted to metastatic disease and predominant histology of SCCE and published in
PubMed during the last decade.
ORR, objective response rate; PFS, progression-free survival; MST, median survival time; PXT, paclitaxel; CDDP, cisplatin; TPF, docetaxel
(TXT)/cisplatin (CDDP)/fluorouracil (FU); CBDCA, carboplatin; Rx, radiation therapy; KDOG 0501, Kitasato digestive disease and oncology group trial;
ADC, adenocarcinoma.
TABLE 6. Overview of Other New Drug Combinations in Metastatic SCCE
Year Author No. of Patients Phase Regimen ORR PFS MST
2009 Lorenzen et al.29 32 PII CET/CDDP/FU 19.0 5.9 9.5
Gong et al.30 39 (inclusion of 3 ADC) PII PTX/NDP 43.6 6.1 10.3
2008 Fujita et al.31 11 Retrospective TXT/NDP 36.3 ND 7.8
Park et al.24 32 PII MMC/IFM/CDDP (MIC) (salvage) 12.5 2.0 5.2
Jonak et al.32 18 (inclusion of 4 ADC) Retrospective ETP/CDDP/FU/LV (FLEP) 22.0 9.2 10.2
Cho et al.34 10 PII S-1/CDDP/Rx 50.0 5.4 11.6
Lee et al.33 45 PII CDDP/XEL (XP) 57.8 4.7 11.2
Lee et al.35 32 PII CDDP/CPT 31.3 4.4 9.6
2002 Conroy et al.36 71 PII VNB/CDDP 33.8 3.6 6.8
2001 Polee et al.6 69 PII ETP/CDDP/FU/FA 34.0 7.0 9.5
Table summarizes previously published comparative studies on other new drug combinations with or without radiation therapy. Studies restricted to
metastatic disease and predominant histology of SCCE and published in PubMed during the last decade.
ORR, objective response rate; PFS, progression-free survival; MST, median survival time; CET, cetuximab; CDDP, cisplatin; FU, fluorouracil; ADC,
adenocarcinoma; PTX, paclitaxel; NDP, nedaplatin; TXT, docetaxel; ND, not determined; MMC, mitomycin C; IFM, ifosfamide; ETP, etoposide; LV,
leucovorin; Rx, radiation therapy; XEL, capecitabine; CPT, irinotecan; VNB, vinorelbine; FA, folinic acid.
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issues of TPF regimen are emerging from the recent reports in
contrast with those of standard FP regimen. The major tox-
icity of TPF was myelosuppression as a representative of
leukopenia and neutropenia. It should be noted that this does
not necessarily cause treatment delay or dose reduction of
TXT. Patients in the TPF group had fewer treatment delays
than did those in the FP group. Posner et al.8 reported that
prolonged neutropenia accounted for the difference and was
responsible for treatment-associated delays in 1% of patients
in the TPF group and 39% of patients in the PF group (P 
0.001). Vermorken et al.7 reported that dose reductions were
made mostly because of nonhematologic toxic effects. In this
study, DLT was grade 4 febrile neutropenia and stomatitis,
similar to previous results from phase I studies on conven-
tional TPF regimens.13 Primary toxicities comprised leuko-
penia, neutropenia, and anorexia, as mentioned earlier. The
frequencies of leukopenia, neutropenia, and anorexia of
grade 3/4 in phase II were 53.8%, 43.6%, and 25.6%,
respectively. Although febrile neutropenia occurred in
15% of the patients, only one developed severe sepsis,
which led to TRD. Careful monitoring for adverse events
is essential during TPF regimen.
Twenty-two patients (56.4%) including 21 outpatients
and 1 inpatient of all the participants received subsequent
chemotherapies as a second treatment; most patients (86.4%)
received two-agent combinations from TXT, platinum, and
FU. TXT plus nedaplatin (DC) combined therapy, for which
favorable results were recently reported, seems especially
suitable for outpatient chemotherapy because of its simplic-
ity.16,22 Because the DC regimen was inferior to TPF in ORR,
but comparable for duration of MST,15 it warrants further
consideration as an optimal second-line regimen.
In summary, the TPF regimen against advanced or
recurrent esophageal squamous cell carcinoma was well tol-
erated and proved superior to other recently reported treat-
ments both in ORR and survival benefit. Similarly, for treat-
ment of gastric cancer and head and neck cancer, TPF can be
expected to be superior to FP treatment. Randomized phase
III studies of the TPF regimen are warranted and urgently
required.
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